Cephalon Inc. has agreed to pay $17 million to settle a spate of class-action shareholder suits filed in 1996 that said top corporate officers hid the truth about the prospects of an experimental drug to treat Lou Gehrig’s disease.

Senior U.S. District Judge Clifford Scott Green yesterday granted preliminary approval of the settlement, clearing the way for notices of it to be published in the Wall Street Journal and mailed to potential class members.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]